Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New inhaled asthma drug shows promise in early trial

NCT ID NCT05276570

Symptom relief Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested an inhaled medication called ARO-RAGE in 127 healthy volunteers and people with asthma. The goal was to check safety and how the drug affects lung function. Participants received one or two doses of the drug or a placebo. Results will help decide if larger studies are warranted.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

127 people

The number who actually took part.

Started

Jun 2022

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Normal pulmonary function tests at Screening (NHVs only) * Confirmed diagnosis of asthma based on source verifiable medical record (asthma patients only) * No abnormal finding of clinical relevance at Screening (other than asthma for asthma patients) * Stable dose of asthma controller medications prior to Screening (asthma patients only) * If on allergen-specific immunotherapy, participants must be on a stable maintenance dose * Non-smoking * Women of childbearing potential must have a negative pregnancy test, cannot be breastfeeding, and must be willing to use contraception. Males must not donate sperm during the study and for at least 12 weeks following the last dose of study drug * Willing to provide written informed consent and to comply with study requirements Exclusion Criteria: * Acute lower respiratory infection or asthma exacerbation within 30 days prior to first dose * Positive COVID-19 test during Screening window * Use of immunosuppressive medication within 90 days prior to first dose * Receipt of any intranasal vaccine within 30 days prior to first dose * Use of systemic corticosteroid therapy within 90 days prior to first dose * Clinically significant health concerns (other than asthma in asthma patients) * Human Immunodeficiency virus (HIV) infection, seropositive for Hepatitis B Virus (HBV), seropositive for Hepatitis C Virus (HCV) * Uncontrolled hypertension * Unwilling to limit alcohol consumption to within moderate limits for the duration of the study * Use of illicit drugs * Use of an investigational agent or device within 30 days prior to first dose Note: additional inclusion/exclusion criteria may apply per protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma

Contacts and locations

Locations

  • Research Site 1

    Nedlands, Washington, 6009, Australia

  • Research Site 1

    Auckland, 1010, New Zealand

  • Research Site 1

    Barcelona, 08017, Spain

  • Research Site 1

    Bangkok Noi, Bangkok, 10700, Thailand

  • Research Site 2

    Auckland, 1051, New Zealand

  • Research Site 2

    Krakow, 31-455, Poland

  • Research Site 3

    Auckland, 622, New Zealand

  • Research Site 3

    Oświęcim, 32-600, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.